{"id":464400,"date":"2021-03-24T11:57:14","date_gmt":"2021-03-24T15:57:14","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=464400"},"modified":"2021-03-24T11:57:14","modified_gmt":"2021-03-24T15:57:14","slug":"investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\/","title":{"rendered":"INVESTOR ALERT: Kaplan Fox Investigates Potential Securities Fraud at AstraZeneca PLC"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, March  24, 2021  (GLOBE NEWSWIRE) &#8212; Kaplan Fox &amp; Kilsheimer LLP (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9fRA6jTkGzSAFDsO_Z363BfMrOACjEdD_NRgJQ27iGuvfZkYKc0t5l-hwrfs9Fs7iD7IsObeatcwn4HUO1H1Ow==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.kaplanfox.com<\/u><\/a>) is investigating claims on behalf of investors who purchased AstraZeneca PLC\u2019s American Depositary Shares (\u201cADSs\u201d) (NASDAQ: AZN) between May 21, 2020 and November 20, 2020 (the \u201cClass Period\u201d).<\/p>\n<p align=\"justify\">A complaint has been filed alleging that Defendants misrepresented and failed to disclose widespread flaws in the design and execution of AstraZeneca\u2019s clinical trials of its COVID-19 vaccine candidate (AZD1222), including that a substantial number of trial participants received half the designed dosage due to a manufacturing error.<\/p>\n<p align=\"justify\">On Nov. 23, 2020, AstraZeneca announced an interim analysis of its trial, revealing that the Company used two different dosing regimens in two smaller scale trials. In one trial, patients received a half dose followed by a full dose (resulting in 90% efficacy).\u00a0 In the other, patients received two full doses (resulting in 62% efficacy). Further, the complaint alleges that AstraZeneca revealed that the half dosing regimen was the result of a manufacturing error discovered early in the trial process and not part of the original trial design.<\/p>\n<p align=\"justify\">Following this news, the price of AstraZeneca\u2019s ADSs declined by about 5% over three trading days to close at $52.60 per share.<\/p>\n<p align=\"justify\">Then, on March 23, 2021, <em>The New York Times<\/em> reported that \u201ca group of medical experts charged with monitoring the company\u2019s clinical trial made a highly unusual accusation: AstraZeneca had essentially cherry-picked data to make its vaccine look better.\u201d<\/p>\n<p align=\"justify\">Following this news, the price of AstraZeneca\u2019s ADSs declined again by about 3.5% to close at $49.40 per share.<\/p>\n<p align=\"justify\">If you are a member of the proposed Class, you may move the court <strong>no later than March 27, 2021<\/strong> to serve as a lead plaintiff for the purported class. You need not seek to become a lead plaintiff in order to share in any possible recovery. If you would like to discuss the complaint or our investigation, please contact us by emailing <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9nsR50nxZ7DNTEbjvzx8u9IskjWadj1V_J_pwLj_bQis0MWchg9ED9wZDB377outTyJibkOEr0rM9N9pigqWpwdP0Fa_p4wue12HbdR8De8=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>pmayer@kaplanfox.com<\/u><\/a> or by calling (646) 315-9003.<\/p>\n<p align=\"justify\">This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p>\n<p align=\"justify\">Kaplan Fox &amp; Kilsheimer LLP, with offices in New York, San Francisco, Los Angeles, Chicago and New Jersey, has many years of experience in prosecuting investor class actions. For more information about Kaplan Fox &amp; Kilsheimer LLP, you may visit our website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9fRA6jTkGzSAFDsO_Z363Nv76kqgxiKPQk9pOFFV1evBR-6jYD6sAfiLCuIh9XP0xcsLLO5SIxeelBfCFkJ8xQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.kaplanfox.com<\/u><\/a>. If you have any questions about this Notice, your rights, or your interests, please contact:<\/p>\n<p align=\"justify\">Donald R. Hall <br \/> KAPLAN FOX &amp; KILSHEIMER LLP <br \/> 850 Third Avenue, 14th Floor <br \/> New York, New York\u00a010022 <br \/> (646) 315-9003 <br \/> E-mail: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-a1URR5zUmvFlXdoodYXsnEiozVvjT2h0mu-1RmOINOq981Es5HjuEdQXlz-d0YDOZ0OMsxza3mViuererpFtGkK8oa7hQttqX4unuLUSVU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>dhall@kaplanfox.com<\/u><\/a><\/p>\n<p align=\"start\">Laurence D. King <br \/> KAPLAN FOX &amp; KILSHEIMER LLP <br \/> 1999 Harrison Street, Suite 1560 <br \/> Oakland, California 94612 <br \/> (415) 772-4704 <br \/> Fax:\u00a0 (415) 772-4707 <br \/> E-mail: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JzP2a3cCemDc51JdTbTczuTI5Rc3r9dlK2aj0jbszlSZ1DIpIVE1AbIjn3JaNfFTk8vnhzHP7rf0R6TV9g5hhTgAwU7k_PUNWh3D0O5-e5o=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>lking@kaplanfox.com<\/u><\/a><\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTgxNCM0MDg5OTk3IzIwMjA4OTE=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/8c595028-8c8f-427f-90eb-22bb181db1c8\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) &#8212; Kaplan Fox &amp; Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors who purchased AstraZeneca PLC\u2019s American Depositary Shares (\u201cADSs\u201d) (NASDAQ: AZN) between May 21, 2020 and November 20, 2020 (the \u201cClass Period\u201d). A complaint has been filed alleging that Defendants misrepresented and failed to disclose widespread flaws in the design and execution of AstraZeneca\u2019s clinical trials of its COVID-19 vaccine candidate (AZD1222), including that a substantial number of trial participants received half the designed dosage due to a manufacturing error. On Nov. 23, 2020, AstraZeneca announced an interim analysis of its trial, revealing that the Company used two different dosing regimens in two smaller scale trials. In one trial, patients &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;INVESTOR ALERT: Kaplan Fox Investigates Potential Securities Fraud at AstraZeneca PLC&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-464400","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>INVESTOR ALERT: Kaplan Fox Investigates Potential Securities Fraud at AstraZeneca PLC - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"INVESTOR ALERT: Kaplan Fox Investigates Potential Securities Fraud at AstraZeneca PLC - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) &#8212; Kaplan Fox &amp; Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors who purchased AstraZeneca PLC\u2019s American Depositary Shares (\u201cADSs\u201d) (NASDAQ: AZN) between May 21, 2020 and November 20, 2020 (the \u201cClass Period\u201d). A complaint has been filed alleging that Defendants misrepresented and failed to disclose widespread flaws in the design and execution of AstraZeneca\u2019s clinical trials of its COVID-19 vaccine candidate (AZD1222), including that a substantial number of trial participants received half the designed dosage due to a manufacturing error. On Nov. 23, 2020, AstraZeneca announced an interim analysis of its trial, revealing that the Company used two different dosing regimens in two smaller scale trials. In one trial, patients &hellip; Continue reading &quot;INVESTOR ALERT: Kaplan Fox Investigates Potential Securities Fraud at AstraZeneca PLC&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-24T15:57:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTgxNCM0MDg5OTk3IzIwMjA4OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"INVESTOR ALERT: Kaplan Fox Investigates Potential Securities Fraud at AstraZeneca PLC\",\"datePublished\":\"2021-03-24T15:57:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\\\/\"},\"wordCount\":448,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNTgxNCM0MDg5OTk3IzIwMjA4OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\\\/\",\"name\":\"INVESTOR ALERT: Kaplan Fox Investigates Potential Securities Fraud at AstraZeneca PLC - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNTgxNCM0MDg5OTk3IzIwMjA4OTE=\",\"datePublished\":\"2021-03-24T15:57:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNTgxNCM0MDg5OTk3IzIwMjA4OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNTgxNCM0MDg5OTk3IzIwMjA4OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"INVESTOR ALERT: Kaplan Fox Investigates Potential Securities Fraud at AstraZeneca PLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"INVESTOR ALERT: Kaplan Fox Investigates Potential Securities Fraud at AstraZeneca PLC - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\/","og_locale":"en_US","og_type":"article","og_title":"INVESTOR ALERT: Kaplan Fox Investigates Potential Securities Fraud at AstraZeneca PLC - Market Newsdesk","og_description":"NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) &#8212; Kaplan Fox &amp; Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors who purchased AstraZeneca PLC\u2019s American Depositary Shares (\u201cADSs\u201d) (NASDAQ: AZN) between May 21, 2020 and November 20, 2020 (the \u201cClass Period\u201d). A complaint has been filed alleging that Defendants misrepresented and failed to disclose widespread flaws in the design and execution of AstraZeneca\u2019s clinical trials of its COVID-19 vaccine candidate (AZD1222), including that a substantial number of trial participants received half the designed dosage due to a manufacturing error. On Nov. 23, 2020, AstraZeneca announced an interim analysis of its trial, revealing that the Company used two different dosing regimens in two smaller scale trials. In one trial, patients &hellip; Continue reading \"INVESTOR ALERT: Kaplan Fox Investigates Potential Securities Fraud at AstraZeneca PLC\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-24T15:57:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTgxNCM0MDg5OTk3IzIwMjA4OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"INVESTOR ALERT: Kaplan Fox Investigates Potential Securities Fraud at AstraZeneca PLC","datePublished":"2021-03-24T15:57:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\/"},"wordCount":448,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTgxNCM0MDg5OTk3IzIwMjA4OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\/","name":"INVESTOR ALERT: Kaplan Fox Investigates Potential Securities Fraud at AstraZeneca PLC - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTgxNCM0MDg5OTk3IzIwMjA4OTE=","datePublished":"2021-03-24T15:57:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTgxNCM0MDg5OTk3IzIwMjA4OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTgxNCM0MDg5OTk3IzIwMjA4OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-kaplan-fox-investigates-potential-securities-fraud-at-astrazeneca-plc-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"INVESTOR ALERT: Kaplan Fox Investigates Potential Securities Fraud at AstraZeneca PLC"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/464400","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=464400"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/464400\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=464400"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=464400"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=464400"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}